Coverage Evaluation Survey of Mass Drug Administration (MDA) to Eliminate Lymphatic Filariasis and Onchocerciasis in South Sudan

Client
Christian Blind Mission (CBM)
Location
Juba, Torit, Ezo, Raja, Jur River, and Mundri East Counties
Sample size
4946
Performance period
June - July 2021

The survey was funded by End Fund and commissioned by CBM and the Ministry of Health South. The evaluation follows an MDA exercise for Albendazole and Ivermectin conducted by the Ministry of Health between February and May 2021 in 47 Counties using a community-directed approach. The purpose of the coverage survey was to validate the reported coverage rates of the 2021 Mass Drug Administration (MDA) of Ivermectin and Albendazole. Specifically, the survey sought to;

  • Determine the proportion of the population treated during the Onchocerciasis and Lymphatic Filariasis MDA campaign
  • Validate reported treatment and geographical coverage rates
  • Determine reasons for non-compliance to treatment with IVM and ALB (Find common reasons as to why individuals did not take part in the MDA by ingesting/swallowing the drug)
  • Identify adverse and serious adverse events (SAEs)
  • Assess’ community knowledge, attitudes, and practices (KAP) on NTDs
  • Identify the methods and channels employed to sensitize and mobilize (Create community awareness) for MDA implementation in the IUs.

The coverage evaluation survey was a household-based survey that applied a cross-sectional study design and followed the WHO implementation guidelines for Coverage Surveys for Preventive Chemotherapy recommended by the WHO Strategic Technical Advisory Group for conducting coverage surveys for NTDs.